Skip to content
Comparison

Mounjaro (Tirzepatide) vs Wegovy (Semaglutide)

Mounjaro (tirzepatide for type 2 diabetes) and Wegovy (semaglutide 2.4 mg for obesity) are frequently compared because many patients use Mounjaro off-label for weight loss and want to understand how it compares to Wegovy. The active ingredients are different — tirzepatide (dual GIP/GLP-1) vs semaglutide (GLP-1 only) — and clinical trial data consistently shows tirzepatide produces more weight loss. However, Mounjaro is only FDA-approved for T2D, while Wegovy is the approved obesity medication. For weight loss in patients without T2D, Wegovy (or Zepbound) is the appropriate brand; for T2D patients also seeking weight loss, Mounjaro is the labeled drug.

4.3(112 ratings)

Quick Answer

Mounjaro (tirzepatide for T2D) and Wegovy (semaglutide 2.4 mg for obesity) have different active ingredients and FDA indications. Tirzepatide (Mounjaro/Zepbound) produces ~20–22.5% body weight loss vs semaglutide's (Wegovy) ~14.9%. For weight management without T2D, Wegovy or Zepbound are the appropriate prescriptions. For T2D patients who also want weight loss, Mounjaro is approved and often produces greater weight reduction than Wegovy-dose semaglutide. Discuss your diagnosis and insurance with your provider.

Head-to-Head Comparison

CriteriaMounjaro (Tirzepatide)Wegovy (Semaglutide)
Active ingredient & mechanismTirzepatide — dual GIP + GLP-1 receptor agonistSemaglutide 2.4 mg — GLP-1 receptor agonist only
Primary FDA indicationType 2 diabetes (Mounjaro) — NOT labeled for obesityChronic weight management in adults with obesity or overweight + comorbidity
Weight loss equivalent (FDA approval doses)~20–22.5% body weight (Zepbound/SURMOUNT-1 at 15 mg) — same molecule~14.9% body weight (STEP-1, 2.4 mg)
Dose available2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly injection0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly injection
Insurance for weight lossNOT typically covered for off-label obesity use — Zepbound is the obesity-labeled brandCovered under obesity/weight management benefits if plan includes them
Insurance for T2DWidely covered for T2D diabetes managementNOT the T2D-labeled brand — Ozempic is the appropriate T2D semaglutide brand
Cardiovascular outcomesSURMOUNT-CVOT ongoing (tirzepatide)SELECT trial: 20% MACE reduction (semaglutide 2.4 mg in patients with obesity + CVD)
Nausea comparison~31% nausea (SURMOUNT-1 / tirzepatide); lower than Wegovy at equivalent efficacy~44% nausea (STEP-1, 2.4 mg semaglutide)
US list price (2026)~$1,060–$1,200/month (Mounjaro)~$1,349–$1,430/month (Wegovy)
OSA indicationYes — Zepbound (same drug) approved for OSA; Mounjaro brand not for OSANo OSA indication

When to Choose Each

Choose Mounjaro (Tirzepatide)

Adults with type 2 diabetes who also want weight loss — Mounjaro is labeled for T2D and produces superior weight reduction vs semaglutide. Also appropriate when insurance covers tirzepatide under T2D benefits.

Choose Wegovy (Semaglutide)

Adults with obesity or overweight with a weight-related comorbidity but without T2D — Wegovy is the correctly labeled obesity medication for this population. Also favored for patients with established cardiovascular disease due to SELECT trial benefit.

Verdict

Comparing Mounjaro and Wegovy head-to-head is somewhat imprecise because they are different drugs approved for different primary indications. For patients with type 2 diabetes who also want weight loss, Mounjaro (tirzepatide) is generally superior — it produces more A1C reduction AND more weight loss than semaglutide. For patients without T2D seeking weight management, Wegovy is the appropriate FDA-labeled medication; if greater efficacy is desired, the analogous brand should be Zepbound (tirzepatide for obesity) — not Mounjaro (tirzepatide for T2D). Insurance coverage largely determines which brand to request based on your primary diagnosis. Consult your provider to identify the right labeled indication and prescription for your specific situation.

References

  1. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
  2. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  3. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed
  4. Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed
  5. Tirzepatide for moderate-to-severe obstructive sleep apnea (SURMOUNT-OSA) (2024) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

From $199/moLearn More →
Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →
Ro BodyBest Value

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

From $149/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Is Mounjaro the same as Wegovy?
No — Mounjaro and Wegovy are different drugs. Mounjaro contains tirzepatide (a dual GIP/GLP-1 receptor agonist) and is FDA-approved for type 2 diabetes. Wegovy contains semaglutide 2.4 mg (a GLP-1 receptor agonist only) and is FDA-approved for obesity. They have different mechanisms, different active ingredients, and different clinical trial data. Tirzepatide (Mounjaro/Zepbound) produces more weight loss than semaglutide (Wegovy/Ozempic) in clinical comparisons.
Which produces more weight loss — Mounjaro or Wegovy?
Tirzepatide (the active ingredient in Mounjaro and Zepbound) produces more weight loss than semaglutide (Wegovy) in clinical trials. SURMOUNT-1 showed tirzepatide at 15 mg produced ~22.5% body weight loss; STEP-1 showed semaglutide 2.4 mg (Wegovy) produced ~14.9%. The SURPASS-2 head-to-head trial confirmed tirzepatide is superior to semaglutide at all doses compared. The approximate advantage is 7–8 percentage points of body weight.
Can I use Mounjaro for weight loss if I don't have type 2 diabetes?
A physician can prescribe Mounjaro off-label for weight loss in patients without T2D, but most insurance plans will not cover it for this use — they require the obesity-labeled brand, which for tirzepatide is Zepbound. The drugs are pharmacologically identical (same tirzepatide molecule, same doses), so the clinical effects are the same. From an insurance perspective, if you want tirzepatide for weight loss and don't have T2D, ask your provider for Zepbound, not Mounjaro.
Which has fewer side effects — Mounjaro or Wegovy?
When comparing tirzepatide vs semaglutide at doses producing equivalent weight loss, tirzepatide tends to cause less nausea. In SURPASS-2, tirzepatide produced ~31% nausea vs ~44% for semaglutide. In SURMOUNT-1 vs STEP-1 (obesity doses), similar patterns hold. Both drugs cause GI side effects (nausea, diarrhea, constipation) that peak during titration and improve over time. Both require slow dose escalation to minimize tolerability issues.
Why does Wegovy cost more than Mounjaro?
At 2026 US list prices, Wegovy (~$1,349–$1,430/month) is generally more expensive than Mounjaro (~$1,060–$1,200/month). Both have manufacturer savings programs. Pricing reflects market positioning, manufacturing costs, and competitive dynamics. With Novo Nordisk's Wegovy savings card, commercially insured patients may pay $0/month; Lilly's Mounjaro savings card offers as low as $25/month. After savings programs, the price difference largely disappears for commercially insured patients.

Explore next